Investigational drug · Phase 2
CM338
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for IgA Nephropathy.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "CM338"
First trial start
2023
May 8, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CM338", any sponsor or status.
Conditions studied
As listed on its trial records.
- IgA Nephropathy
Approved drugs for the same conditions: IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "CM338" as an intervention, largest first.
Keymed Biosciences Co.LtdIndustry
NCT05775042 · 70 participants (planned) · Start May 8, 2023 · Primary completion Jun 30, 2027
Drug: CM338 · For: IgA Nephropathy
Sites: Beijing, China
Keymed Biosciences Co.LtdIndustry
NCT05186285 · 66 participants · Start Dec 11, 2021 · Primary completion Jul 27, 2022
Drug: CM338; Placebo · For: Healthy
Sites: Zibo, China
Keymed Biosciences Co.LtdIndustry
NCT05371379 · 48 participants · Start May 24, 2022 · Primary completion Nov 4, 2022
Drug: CM338 Injection · For: Healthy Subjects
Sites: Zibo, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for IgA Nephropathy
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
- FUB523zigakibart, BION-1301Phase 36 trials
Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)
- SCTC21CPhase 34 trials
Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)
- JADE101Phase 32 trials
Jade Biosciences, Inc. · IgA Nephropathy (IgAN), IgA Nephropathy
- BHV-1400Phase 31 trial
Biohaven Therapeutics Ltd. · IgA Nephropathy
- NM8074Phase 28 trials
NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria
- XH-S003Phase 22 trials
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy
- ADX-097Phase 21 trial
Akebia Therapeutics · IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.